ACT319-101: Lutetium-177 (177Lu-ACT319) for fibroblast activation protein (FAP)-expressing pancreatic ductal adenocarcinoma, biliary tract carcinoma and other FAP-expressing solid tumours (ANZCTR) - Oct 2, 2026 - P1/2 | N=182 | Not yet recruiting | Sponsor: Actithera, Inc.
New P1/2 trial • Biliary Cancer • Biliary Tract Cancer • Breast Cancer • Colorectal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • FAP
|